Professor J Harvey Turner is a senior clinical academic consultant physician and nuclear medicine oncologist at the University of Western Australia. He founded the Department of Nuclear Medicine at Fremantle Hospital in 1976 and practised as Consultant physician in General Medicine and Director of Nuclear Medicine until transfer of the Department to Fiona Stanley Hospital in 2015. His research focused upon radiopharmaceutical theranostics and he has specialised in design and performance of early phase clinical trials of radiopeptide therapy of neuroendocrine tumours and radioimmunotherapy of lymphoma. He pioneered the combination of radiosensitizing chemotherapy in conjunction with tumour- targeted radionuclide treatment with Iodine-131 and Lutetium-177.
He performed the first Phase I and II trials of Samarium-153 diphosphonate palliation of metastatic bone cancer in the late 1980’s for which he was awarded a Doctorate in Medicine by the University of Melbourne in 1990. Since then he published nearly a hundred innovative clinical studies in the international literature. His encouraging results in Gastro-Entero-Pancreatic NeuroEndocrineTumours treated with 177 Lu-octreotate capecitabine temozolomide radiopeptide- chemotherapy led to the CONTROL-NETs randomised controlled Phase II multicentre Australian clinical trial.
Professor Turner founded the World Radiopharmaceutical Therapy Council of the World Federation of Nuclear Medicine and Biology (WFNMB) and is a Past President of the World Association of Radiopharmaceutical and Molecular Therapy (WARMTH). He serves on the editorial boards of the World Journal of Nuclear Medicine, Annals of Nuclear Medicine and Cancer Biotherapy and Radiopharmaceuticals and has written a book on the Natural History of Cancer. Professor Turner has given several invited keynote presentations on Theranostic Nuclear Oncology at international congresses and he was awarded the Pioneer Lectureship of the ANZSNM at the World Congress of WFNMB in 2018.